Unfortunately, the last two sections are less satisfying. Dr. Wilens covers the most common psychiatric conditions encountered in clinical practice, defining and discussing each disorder and a general treatment approach, as well as the role of medications. In the final section, he reviews each class of psychotropics, including their putative mechanism of action, common indications, typical dosing ranges, and adverse effects. Although there is a dearth of controlled trials in the area, one can extrapolate from the clinical trial experience in adults to provide at least some initial guidance. In this context, I found the discussions on the use of antipsychotic agents problematic, with a tilt toward the use of neuroleptics over the latest generation of novel agents. In particular, the timing and duration of treatment in this younger age group may substantially increase total drug exposure, resulting in an increased risk of adverse neurological events such as tardive dyskinesia. Indeed, this concern has fueled the shift to novel agents as first-line treatments in adults. More troubling is the recommendation that neuroleptics may be used in the management of conditions such as conduct disorder and oppositional defiant disorder (p. 143), dissociative episodes associated with posttraumatic stress disorder (pp. 164, 167), and more severe sleep disorders (p. 186). Surely, we can recommend less risky approaches.